Navigation Links
Cardiac Science Announces Data Connectivity with LUMEDX

Innovative firms partner to improve workflow and data connectivity for

Cardiac Rehabilitation

BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, announced today that its new cardiac rehab system, Q- Tel RMS(R) 3.0, now has seamless connectivity with LUMEDX CardioWellness(TM) data management software.


The integration of rehabilitation data from the Q-Tel RMS 3.0 system into CardioWellness enables the best possible treatment decisions. The combination allows caregivers to seamlessly integrate data from the Q-Tel RMS 3.0 rehabilitation system into CardioWellness, creating a comprehensive diagnosis and treatment plan tuned specifically to the patient's gender specific needs. By applying this gender-specific understanding of the patient's disease state to the rehabilitation treatment, outcomes can be improved.

"Cardiac Science is dedicated to helping its customers improve their workflows and improve access to data, facilitating the best possible treatment decisions," said Ren Mitchell, director of diagnostic marketing at Cardiac Science. "In response to feedback from clinicians, the Q-Tel RMS 3.0 features enhanced connectivity capabilities to improve rehab center workflow, while maintaining the heritage of reliability and high performance of the Q-Tel family of rehabilitation management systems. We believe that this collaboration with LUMEDX will improve patient care and better meet the needs of our customers."

"CardioWellness can help facilities grow their gender-specific cardiovascular care programs with its sophisticated database for tracking patients from risk assessment through treatment," said Randy Marc Lasnick, director of marketing at LUMEDX Corporation. "Research has shown that gender- specific care can provide patients with better outcomes. We believe that by providing a direct link between CardioWellness and Q-Tel RMS 3.0, the leading cardiac rehabilitation system, we can provide greater value to these facilities by bringing an added layer of critical rehab data into the clinical decision making process."

Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science's superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.

For more information about the Q-Tel RMS 3.0, please call 800.679.8703.


Founded in 1990, LUMEDX is the market leader in developing end-to-end cardiovascular information and imaging systems. Providing consulting services, training, and the CardioStar(TM) software suite-the most comprehensive suite of fully integrated cardiovascular information tools-LUMEDX delivers complete clinical and business solutions for heart centers.

About CardioWellness

CardioWellness is a comprehensive set of tools and support programs to help heart centers grow their own successful gender-specific CV centers. CardioWellness recognizes the differences in presentation, diagnostic testing, risk assessment, and outcomes for men and women. These differences are built into the way patients are diagnosed, treated, and tracked throughout the continuum of care.

About Q-Tel RMS 3.0

The Q-Tel RMS system is a state-of-the-art, comprehensive cardiac monitoring and data management system developed to meet the needs of cardiac rehabilitation programs. Designed with efficient workflow and integration to EMR and HIS systems in mind, the Q-Tel family of Rehabilitation Management Systems is designed to enable the best possible treatment decisions.

About Cardiac Science Corporation

Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark; and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our alliance with LUMEDX will contribute to our success in the marketplace, and that our sales and profits derived from our cardiac rehabilitation and monitoring devices and our other products will increase as a result. These statements, including their underlying assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Other risk factors that could cause or contribute to such varying results are described in our annual report for the year ended December 31, 2006, filed with the Securities and Exchange Commission.

The statements in this press release speak as of the date of the release, and Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Company Contact:

Mike Matysik

Cardiac Science Corporation

Sr. Vice President and CFO


Investor Contact:

EVC Group, Inc.

Douglas Sherk/Jenifer Kirtland


Media Contact:

EVC Group, Inc.

Jen Saunders


SOURCE Cardiac Science Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Gene HPA-2 Met linked to cardiac arrest
3. Defibrillators In Public Places Will Help Cardiac Patients
4. Supplement helps cardiac surgery
5. Cardiac diseases develop early
6. Latest device for cardiac revival under test
7. Bone marrow stem cells may help repair cardiac tissues
8. Heart problems detected better with a Cardiac MRI
9. Cardiac events better treated with intense cholesterol-lowering regime
10. Sudden Cardiac Death due to inherited Heart Disease
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
Post Your Comments:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... -- Lannett Company, Inc. (NYSE: LCI ) today ... Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty ... S.A. (Euronext: UCB). --> ... UCB for total consideration of approximately US$1.23 billion, ... capital adjustment, a deduction of certain reimbursable amounts ...
(Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 2015 --> --> ... to find optimal contrast weighting of MRI for patients ... signed a research agreement with SyntheticMR in order to use ... it is possible to generate multiple contrast images from a ... has left, thus making it possible to both fine tune ...
Breaking Medicine Technology: